|
|
| | alpha-Helical CRF (9-41) Basic information |
| Product Name: | alpha-Helical CRF (9-41) | | Synonyms: | CORTICOTROPIN RELEASING FACTOR ANTAGONIST;H-ASP-LEU-THR-PHE-HIS-LEU-LEU-ARG-GLU-MET-LEU-GLU-MET-ALA-LYS-ALA-GLU-GLN-GLU-ALA-GLU-GLN-ALA-ALA-LEU-ASN-ARG-LEU-LEU-LEU-GLU-GLU-ALA-NH2;ASP-LEU-THR-PHE-HIS-LEU-ARG-GLU-MET-LEU-GLU-MET-ALA-LYS-ALA-GLU-GLN-ALA-GLU-GLN-ALA-LEU-ASN-ARG-LEU-LEU-GLU-ALA-NH2;ASP-LEU-THR-PHE-HIS-LEU-LEU-ARG-GLU-MET-LEU-GLU-MET-ALA-LYS-ALA-GLU-GLN-GLU-ALA-GLU-GLN-ALA-ALA-LEU-ASN-ARG-LEU-LEU-LEU-GLU-GLU-ALA-NH2;ALPHA-HELICAL CORTICOTROPIN RELEASING FA CTOR;α-helical corticotropin releasing factor fragment (9-41);ALPHA-HELICAL CORTICOTROPIN RELEASING FACTOR (9-41);ALPHA-HELICAL CORTICOTROPIN RELEASING FACTOR FRAGMENT (9-41) | | CAS: | 99658-03-4 | | MF: | C22H25IN2O6 | | MW: | 540.34817 | | EINECS: | | | Product Categories: | CRF receptor and related | | Mol File: | 99658-03-4.mol |  |
| | alpha-Helical CRF (9-41) Chemical Properties |
| storage temp. | −20°C | | form | powder | | color | white |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | alpha-Helical CRF (9-41) Usage And Synthesis |
| Uses | α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2]. | | Biochem/physiol Actions | The corticotropin releasing factor (CRF) antagonist α-helical CRF [9-41] exhibits 10-fold higher affinity for rat CRF2α receptors over human CRF2α receptors. It has been used to elucidate the role of CRF in various physiological systems. In colonic epithelium, it abolishes CRF-induced changes in ion secretion, and significantly inhibits CRF-stimulated conductance. It antagonizes the CRF-induced proinflammatory degranulation of perivascular mast cells that are activated in response to acute psychological stress and CRF secretion. | | in vivo | α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values[1].
α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity[2]. | Animal Model: | Adult Sprague-Dawley rats[1] | | Dosage: | 10 μg | | Administration: | The third or lateral ventricle of the brain injection; 10 μg once | | Result: | Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress.
|
| Animal Model: | Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)[1] | | Dosage: | 10 μg | | Administration: | Lateral ventricle brain injection; 10 μg once | | Result: | Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF).
|
| Animal Model: | Male Wistar rats with rhlL-1/β injection[2] | | Dosage: | 100 ng/kg | | Administration: | Intracerebroventricularly injection; 100 ng/kg once | | Result: | Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β.
|
| | References | [1] Rivier C, Vale W. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology. 1985 Dec;117(6):2478-82. DOI:10.1210/endo-117-6-2478
[2] Takakazu Oka, et al. Intracerebroventricular injection of interleukin-1/β induces hyperalgesia in rats. Brain Research, 624 (1993) 61-68. |
| | alpha-Helical CRF (9-41) Preparation Products And Raw materials |
|